Evaluating Inhibitor Risk Following Factor Product Switches – Results from ATHN 2
American Thrombosis and Hemostasis Network (ATHN) shared a post on LinkedIn about a recent article by Erin Cockrell et al., published in Haemophilia, adding:
“New ATHN research published in Haemophilia provides important real-world evidence on factor product switching.
The ATHN 2: Factor Switching Study found no new inhibitor development among previously treated people with hemophilia A or B following a factor product switch among participants with evaluable follow-up.
Thank you to the participants, investigators, and ATHN-affiliated sites who made this work possible.
We are especially grateful for the contributions of the late Dr. Janna Journycake, Co-PI of ATHN 2.
Janna’s scientific leadership, dedication, and vision were an important part of this work and of the foundation upon which ATHN 2 was built.
Her impact continues to be felt today, and we are honored to recognize her enduring legacy through this publication and the work that continues because of it.”
Title: Lack of Inhibitor Development in Previously Treated People With Haemophilia Switching Factor Products—Final Results of Athn 2: Factor Switching Study
Authors: Erin Cockrell, Martin Chandler, Tammuella Chrisentery-Singleton, Stacy E. Croteau, Nabil Daoud, Michael F. Guerrera, M. Nikki Hirsh, Janna Journeycake, Roshni Kulkarni, Susan U. Lattimore, Catherine McGuinn, Margaret Ragni, Michael Recht, Ulrike M. Reiss, Robert Sidonio Jr., Cliffford M. Takemoto, Michael Tarantino, Annette von Drygalski, Ellis J. Neufeld
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?
-
Sep 5, 2026, 15:24Mayer Hany: Recombinant Activated FVII in Spontaneous Intracerebral Hemorrhage
-
Sep 5, 2026, 15:09Consuela A. Albright: Clinical Advocacy in Sickle Cell Disease
-
Sep 5, 2026, 15:00Brandon Buck: Human Cell-Free DNA as a Diagnostic Tool for Aging and Rare Blood Disorders
-
Sep 5, 2026, 14:57Archil Jaliashvili: What if Normal Hb and SpO₂ Still Do not Mean Adequate Tissue Oxygenation?
-
Sep 5, 2026, 14:50Sandrine Oziel-Taieb: Hematological Toxicity Management During Lu-Dotatate
-
Sep 5, 2026, 14:43Nandini Pethe: How Digital Logs Help Recognize Pediatric von Willebrand Disease
-
Sep 5, 2026, 14:36Aremu David: From Hemophilia Camp Friendship to Digital Innovation in Tic Tac Toe
-
Sep 5, 2026, 13:05Sheharyar Raza: Threshold-Based Transfusion in Sickle Cell Disease